For the Inventor, By the Inventor

Enter assignee name

Pohang, South Korea

Bioapplications Inc.

USPTO Granted Patents = 20

% Expired Patents = 25.0

CIPO Patents = 1

EPO Patents = 1

Forward Citations = 58

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Yongjik Lee (8 out of 8 patents)

Don B Hennig (5 out of 6 patents)

In Hwan Hwang (4 out of 4 patents)

4. Jeffry L VanElverdinghe (4 out of 36 patents)

5. Jae-Young Song (4 out of 4 patents)

6. Hyang Ju Kang (3 out of 4 patents)

7. Yong Jik Lee (3 out of 4 patents)

8. Eun Ju Sohn (3 out of 4 patents)

9. In-Ohk Ouh (3 out of 3 patents)

10. Sangmin Lee (2 out of 97 patents)

11. Inhwan Hwang (2 out of 7 patents)

12. In-Soo Cho (2 out of 2 patents)

13. Eun-Ju Sohn (2 out of 3 patents)

14. Ju-Yeon Lee (2 out of 2 patents)

15. Soo Dong Cho (2 out of 2 patents)

20 patents: Sort by Forward Citations

1. 12385056 - Method for mass production of target protein in plant (2025-08-12),

2. 12357686 - Porcine epidemic diarrhea (PED) virus vaccine composition and preparation method thereof (2025-07-15),

3. 12357685 - Vaccine composition for preventing rabies, and preparation method thereof (2025-07-15),

4. 12156907 - Recombinant vector for expressing virus-like particles in plant and method for preparation of vaccine composition containing circovirus-like particles by using same (2024-12-03),

5. 12097255 - Recombinant porcine parvovirus antigenic protein and use thereof (2024-09-24),

6. 11958883 - Recombinant canine parvovirus 2a VP2 and 2b VP2 antigen protein, and use thereof (2024-04-16),

7. 11845945 - Recombinant vector for expressing target protein in plant cell (2023-12-19),

8. 11484589 - Vaccine composition for classical swine fever and preparation method thereof (2022-11-01),

9. 11434496 - Recombinant vector comprising BiP fragment and preparation method of recombinant proteins using thereof (2022-09-06),

10. 11279943 - Recombinant vector for expressing target protein in plant cell (2022-03-22),

11. 10947278 - Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof (2021-03-16),

12. 10934558 - Recombinant vector carrying cellulose binding domain and method for isolating and purifying protein, using same vector (2021-03-02),

13. 10857217 - Antigen fused with porcine Fc fragment and vaccine composition comprising the same (2020-12-08),

14. 10344293 - Vaccine composition for classical swine fever from plant and manufacturing method thereof (2019-07-09),

15. 9512173 - Method for separating and purifying protein from plants using cellulose and cellulose binding domain (2016-12-06),

Company Overview

Bioapplications Inc. is a South Korean company specializing in the development and manufacturing of innovative biotechnological solutions. The organization focuses on creating advanced medical devices and applications that enhance healthcare delivery and improve patient outcomes. With a commitment to research and development, Bioapplications is at the forefront of integrating biotechnology into practical applications, contributing to the evolving landscape of medical technology and life sciences.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

20 Patents

#5 in Pohang

#631 in South Korea

#31,233 in the World

Pohang, South Korea

Bioapplications Inc.

Forward Citations = 58

37 inventors:

Yongjik Lee (8 out of 8 patents)

Don B Hennig (5 out of 6 patents)

In Hwan Hwang (4 out of 4 patents)

4. Jeffry L VanElverdinghe (4 out of 36 patents)

5. Jae-Young Song (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bioapplications Inc.. Retrieved from https://idiyas.com/company/bioapplications

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…